A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

Trial Details

NCT ID
NCT07085091
Phase
PHASE1
Sponsor
ALX Oncology Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ALX2004
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Santa Monica, California, United States|34.01949,-118.49138
  • Tampa, Florida, United States|27.94752,-82.45843
  • Farmington Hills, Michigan, United States|42.48531,-83.37716
  • Grand Rapids, Michigan, United States|42.96336,-85.66809

Key Eligibility Criteria

  • Participants with locally advanced, recurrent or metastatic histologically confirmed HNSCC, NSCLC, ESCC, CRC; locally advanced or recurrent disease…
  • Dose Escalation: Participants who have relapsed or progressed following prior anticancer therapy in the advanced/metastatic setting and for whom no…
  • Dose Exploration and Dose Expansion: The following tumor-specific criteria also apply. These cohorts will include all or a subset of these tumors.
  • HNSCC - Received no more than 3 prior lines of therapy in the advanced or metastatic setting

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →